HK2 and neoplasm: In addition, they showed that the use of the proteasome inhibitor bortezomib in the presence of genetic inhibition of HK2 after transplantation of KMS-11 cells into immunodeficient mice or pharmacological inhibition of HK2 by 3-bromopyruvate leads to a significant tumor reduction and an increase in apoptosis induction in MM cells, respectively [33].